Post-prostatectomy radiotherapy (RT) is a common second-line treatment for patients with prostate cancer. In the phase III randomized NRG-GU003 trial, hypofractionated postprostatectomy RT (HYPORT) was compared with conventionally fractionated postprostatectomy RT (COPORT) in terms of patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms in patients with prostate cancer who had received prostatectomy. Overall, 296 patients were randomized to receive HYPORT (144) or COPORT (152). No differences in the patient-reported GU symptoms were observed after RT in the HYPORT versus the COPORT group, and these results were maintained at 6 and 12 months post-RT. Patient-reported GI symptoms were greater in patients receiving HYPORT than patients in the COPORT group at the end of the RT treatment, but this difference was abolished within 6 months. At the median follow-up time of 2.1 years, no differences in GI and GU symptoms were reported between the two groups of patients. These results indicate that HYPORT can be a new acceptable practice standard for patients with prostate cancer after prostatectomy, with the benefit of reducing time commitment and treatment-associated expenses, potentially increasing access to therapy.

前列腺切除术后放疗（RT）是前列腺癌患者常见的二线治疗方法。在 III 期随机 NRG-GU003 试验中，将大分割前列腺切除术后放疗 (HYPORT) 与传统分割前列腺切除术后放疗 (COPORT) 进行比较，评估接受过治疗的前列腺癌患者报告的泌尿生殖 (GU) 和胃肠道 (GI) 症状。前列腺切除术。总体而言，296 名患者被随机分配接受 HYPORT (144) 或 COPORT (152) 治疗。 HYPORT 组与 COPORT 组在 RT 后观察到患者报告的 GU 症状没有差异，并且这些结果在 RT 后 6 个月和 12 个月保持不变。在 RT 治疗结束时，接受 HYPORT 的患者报告的胃肠道症状比 COPORT 组的患者更大，但这种差异在 6 个月内消失。中位随访时间为 2.1 年，两组患者的胃肠道和胃肠道症状没有差异。这些结果表明，HYPORT 可以成为前列腺切除术后前列腺癌患者可接受的新实践标准，其优点是减少时间投入和治疗相关费用，有可能增加获得治疗的机会。